The Common of Side Effects of Pegylated Interferon Treatment in Hepatitis B and Hepatitis C Patients: Systematic Review


  • Rachellita Pujadimarta Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Ummi Maimunah Division of Gastroenterology and Hepatology, Dr. Soetomo General Hospital, Surabaya, Indonesia
  • Maftuchah Rochmanti Departement of Pharmacology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia


Hepatitis B, Hepatitis C, Side Effects, Pegylated Interferon, SDGs


 Pegylated Interferon (Peg-INF) therapy which has various side effects and is relatively severe. The side effects that occur in each individual are different, some patients treated with Peg-INF have experienced mild to severe side effects. Evaluation The side effects of Peg-INF on chronic hepatitis B and / or C have not been widely reported. Thus, I will conduct research on the side effects of Peg-INF therapy in chronic hepatitis B and / or C patients by combining two or more research results that can be combined to obtain new quantitative data. The purpose of this study was to determine the side effects of Peg-INF treatment in chronic hepatitis B and C patients.  This research uses the Systematic Review method. With the keyword "Efek Samping Pegylated Interferon"; "Pegylated Interferon successful treatment"; Pegylated Interferon Hepatitis in Asia”. As a result total of 19 journal articles were obtained and the side effects of Peg-INF were hematological, systemic, psychiatric, autoimmune and hearing function side effects.


. Ashley M, Onyema M. “Pegylated interferon alpha 2A for the treatment of hepatitis C virus infection” Expert opinion on drug metabolism and toxicology, 14(2); 219-227. 2018.

. Asnis GM, De La Garza R. “Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches” J Clinic Gastroenterol, 40 (4): 322- 335.2006.

. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. “Pegylated interferon and ribavirin in haemodialysis patients” Nephrology Dialysis Transplantion, 21(5): 1444-1445. 2006.

. Cetin K, Ozlem M S, Bulent B, Asli C O, Suut G, Esra A, Sami E, Filiz A, Kadir D, Fatih B, Sabahattin K. “Efficacy of pegylated interferon- alpha treatment for 24 months in chronic delta hepatitis and predictors of respons” International Medical Press, 18: 561-566. 2013.

. Calvaruso V, Mazza M, Almasio P L. “Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects”. Expert Opinion on Drug Safety, 10(3):429–435.2011.

. Chen H L, Chung F H, Chun J L, Chia Y D, Cheng C L, Jee-Fu H, Peir H H, Hung B S., Meng K S, Shih I C, Jou W L, Sheng S Y, Tung H S, Hung C Y, Pei J C, Ding S c, Wan L C, Ming L Y, Jia H K. “Pegylated Interferon Alpha 2A or without low dose ribavirin for treatment- naïve patients with hepatitis c virus genotype 1 receiving hemodialysis”. Annal of internal medicine, Vol 159: 729-738.2017

. Dosouky, Ibtesam., Elhawari, Soha., Emara, Mohamed., Hamed, Emad. “Types and Predictors of Interferon/Ribavirin Induced Cardiac Complications in The Egyptian Patients With Chronic Hepatitis C Virus”. Faculty of Medicine Zagazig University Egypt. Vol 20: 643-653. 2014.

. Dong J S, Han C L, Kwan S B, Mong C, Young O K, Won Y T, Chae Y C, Kwang C K, Young S L. “Efficay and safety of pegylated interferon -alpha 2A in patients with lamivudine – resitant HBeAg- positive chronic hepatitis B”. Antiviral Therapi. 18: 765-773. 2013.

. Dan A A, Martin L M, Crone C, Ong J P, Farmer D W, Wise T, Younossi Z M. “Depression anemia and health related quality of life in chronic hepatitis C”. Journal of hepatology, 44(3): 491-498. 2006

. Eleanor L M. “Preclinical and Clinical Development of Pegylated Interferon”. Journal of Interferon & Cytokine Research, 30 (8): 591-598. 2010

. Elif D Kartal, Saygin N A, Ilhan O, Gaye U. “Adverse effects of high – dose interferon -alpha 2A treatment for chronic hepatitis B”. Advances in therapy. 24: 963. 2007.

. Francis E Lotrich. “Psychiatric Clearance for Patients Started on Interferon Alpha Based Therapies”. Am J Psychiatry, 170:6. 2013.

. Gulden E K, Turgut K, Kutbetiin D, Erol K. “The Effects of Pegylated Interferon/ Lamivudin Therapy on Auditory Function in Patients with Hepatitis B”. Auris Nasus Larynx International Journal of ORL &HNS, Vol 38: 312-318. 2011.

. Gökhan K, George N D, Yìlmaz Ç, Kalliopi Z, Thomas b, Andreas E, Stefan Z, Fehmi T, Kendal Y A, Mithat B, Hans P D, Hakan B, Michael M, Heiner W, Cihan Y. “Pegylated Interferon Based Treatment in Patients With Advanced Liver Disease due to Chronic Delta Hepatitis”. Turk Journal Gastroenterol, 23(5): 560-568. 2012.

. Haris P, Murali S R, Martin M, Sonu D, Paul M. “Deppresion and pegylated Interferon – Based Hepatitis C Treatment”. International Journal of Interferon, Cytokin, and Mediator Research. Vol: 4, 25-23. 2012.

. Hubert S, Michael C, Sammy S. “Management of hepatitis c antiviral therapy adverse effect”. Current hepatology reports. 10: 33-40. 2011.

. Janina K, Marta W S, Waldemar U, Jakub P, Anhelli S. “The influence of interferon alpha on the induction of autoimmune thyroiditis in patients treated for chronic viral hepatitis type C”. Endokrynologia Polska, 62(6):517-22 . 2011.

. Kelly F N D, Angelo A M, Christiane V T, Fernanda W O, Leandro C, Alberi A F, Christofali B, Paulo R L A. “Impact of the pegylated interferon and ribavirin therapy on the treatment related mortality of patients with cirrhosis due to hepatitis c virus”. Revista do instituto de medicina tropical de sao Paulo, 58: 37. 2016.

. Kan K, Takashi A, Kosaku N, Ikuto M, Ryoichi, Namiki I, Masanori A, Chikao Y, Fumi K, Naoki H, Yoahihiro T, Etsuro O, Kazuhiko H, Masaki N, Hiroshi K, Masanor K, Hiroyuki K, Norisato, Hideki, Misaki M, Michio I, Tadao A. “Multicenter study of pegylated interferon alpha-2A monotherapy for hepatitis C virus infected patients on hemodyalisis: Reach study”. Therapeutic Apheresis and Dialysis, 18(6): 603-611. 2014.

. Kokoglu O F, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese M A, Isik I O. “Efficacy and tolerability of pegylated interferon alpha-2a in hemodyalisis patients with chronic hepatitis C”. Journal of gastroenterology and hepatology, 21 (3): 575-580. 2006.

. Mario E, Jesus H, Maria D A, Fernando C, Carlos C, Fabrizio F. “Pegylated interferon alone or with ribavirin for chronic hepatitis c in haemodialysis population”. Kidney blood Press Res, 40(3): 258-65. 2015.

. Maryam A, Jason G, Gail V M, Kathy P, Barbara Y, Carolyn D, Andrew R L, Ingrid V B, John M K, Margaret H, Gregory J D, Paul S H. “Effect of pegylated interferon alpha-2a treatment on mental health during recent hepatitis c virus infection”. Journal of gastroenterology and hepatology, 27: 957-965. 2012.

. Michel B, Victor P, Valentin C, Lilia C, Pavline J, Jeffrey, A, Peter S, Frederic L G, Emmanuel G, Adalbert K H, Hadi K, Michael R, Andrew V. “Safety and efficacy of REP 2139 and pegylated interferon alpha-2A for treatment- naïve patients with chronic hepatitis b virus and hepatitis d virus co-infection ( REP 301and REP 301-LTF): a non randomized, open label, phase 2 trial”. Lancet Gastroenterol Hepatol, 2 (12): 877-889. 2017.

. Muhammad A M, Asif M, Muhammad A F, Ghias U N T, Israr U H T. “Hypothiroidsm in hepatitis c patients on pegylated interferon therapy”. J ayub med coll Abottabad, 20(4): 706- 708. 2016.

. Nikolina B J, Marijana G, Jasna S, Valentina C M, Bosilijka I, Sanjin R, Nilenka S, Rajko O, Irena H, Dragan L, Boris V, Petar K. “Pegylated interferon for treatment of chronic hepatitis c in hemodialysis patients in Croatia”. Kidney Blood Pressure Research, 34: 53-57. 2011.

. Nurdjanah, Siti. “Therapy for Chronic Viral Hepatitis”. The Indonesiam Journal of Gastroenterology, Hepatology, and Digestive Endescopu, Vol 2(1). 2001.

. Sanjaya K S, Chandra S L, Shawnette P, Shobhana C, Susan W. “ Equally Poor Outcomes to Pegylated Interferon – based Therapy in African American and Hispanics with Chronic Hepatitis C Infection”. J Clinic Gastroenterol, Vol. 44 No.2. 2010.

. Serrano-Villar S, Quereda C, Moreno A, Pérez-Elías M J, Casado J L, Royuela A, Moreno, S. “Neutropenia During Therapy With Peginterferon and Ribavirin in HIV-Infected Subjects With Chronic Hepatitis C and The Risk of Infection”. Clinical Infectious Diseases, 57 (3): 458-464. 2013.

. Tan S S, Abu Hassan M R, Abdullah A, Ooi B P, Korompis T T, Merican M I. “Safety and Efficacy of an Escalating Dose Regimen of Pegylated Interferon alpha 2B in The Treatment of Haemodialysis Patients with Chrronic Hepatitis C”. Journal of Viral Hepatitis, Vol 17, 410-418. 2010.

. Teresa S, Massimo F, Evangelista S, Paulo T, Sergio B, Paolo F, Mario T, Giovanni D P, Nicoletta M, Eligio P, Gioacchino A. “Acute Hepatitis C: A 24 – Week Course of Pegylated Interferon Alpha 2b Versus a 12- Week Course of Pegylated Interferon Alpha -2B Alone or with Ribavirin”. Official Journal of The American Association for The Study of Liver Disease, Vol. 59, No. 6. 2014.

. Peck–Radosavljevic, M, Wichlas M, Homoncik–Kraml, M, Kreil, A, Hofer, H, Jessner, W, Ferenci, P. (2002). “Rapid suppression of hematopoiesis by standard or pegylated interferon-α”. Gastroenterology, 123(1):141–151. 2002.

. Pierre Deltenre. “Studies on the epidemiology of hepatitis B and C virus infections are still needed”. J Hepatol, 62(6): 1225-7. 2015.

. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. “The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C”. Am J Gastroenterol, 89 (3): 399-403. 1994.

. Zehui Y, Ke F, Yi F, Xiaohong W, Qing M, Guohong D, & Yuming W, Don J S, Han C L, Kwan S B, Mong C, Young O K, Won Y T, Chae Y C, Kwang C K, Young S L. 2013. “Efficacy and Safety of Pegylated Interferon alpha2A in Patients, with Lamivudine – Resistant HBeAG-Positive Chronic Hepatitis B”. International Medical Press, 18:765-773. 2013.

. Zorana P, Dragan D, Nadja P M, Olivera V, Miroslava J G. “Depressive symptoms in patients with hepatitis c treated with pegylated interferon alpha therapy: a 24 week prospective study”. Psychiatria Danubina. 23(4): 370-377. 2011.

. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al. “A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C”. Mol psychiatry, 7:942-7. 2002.




How to Cite

Pujadimarta, R. ., Maimunah, U. ., & Rochmanti, M. . (2021). The Common of Side Effects of Pegylated Interferon Treatment in Hepatitis B and Hepatitis C Patients: Systematic Review. International Journal of Sciences: Basic and Applied Research (IJSBAR), 60(1), 120–130. Retrieved from